| Catalym–Bavaria (govt): investment, 202211 financing round Series C totalling €50m incl existing + co-investor Bayern Kapital |
2022-11-22 |
| Catalym–BioGeneration Ventures: investment, 202211 financing round Series C totalling €50m incl existing + co-investor BGV |
2022-11-22 |
| Catalym–Brandon Capital: investment, 202211 financing round Series C totalling €50m incl new + co-lead investor Brandon Capital |
2022-11-22 |
| Catalym–Forbion: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Forbion |
2022-11-22 |
| Catalym–Germany (govt): investment, 202211 financing round Series C totalling €50m incl existing + co-investor Coparion |
2022-11-22 |
| Catalym–Jeito Capital: investment, 202211 financing round Series C totalling €50m incl new + co-lead investor Jeito Capital |
2022-11-22 |
| Catalym–Novartis: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Novartis Venture Fund |
2022-11-22 |
| Catalym–SEVERAL: investment, 202211 financing round Series C €50m led by Brandon Capital + Jeito Capital |
2022-11-22 |
| Catalym–Trophic Communications: public relations, 202211 service existent by Trophic |
2022-11-22 |
| Catalym–Vesalius Biocapital: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Vesalius Biocapital III |
2022-11-22 |
| FogPharma–HBM: investment, 202211 financing round Series D totalling $178m incl existing investor HBM Healthcare Investments |
2022-11-21 |
| FogPharma–SEVERAL: investment, 202211 financing round Series D $178m from existing + new investors |
2022-11-21 |
| Cradle Bio–Index Ventures: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Index Ventures |
2022-11-17 |
| Cradle Bio–Kindred Capital: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Kindred Capital |
2022-11-17 |
| Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Emily LeProust |
2022-11-17 |
| Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Feike Sijbesma |
2022-11-17 |
| Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Sylvain Gariel |
2022-11-17 |
| Cradle Bio–SEVERAL: investment, 202211 emerges from stealth with €5.5m seed financing round led by Index Ventures + Kindred Capital |
2022-11-17 |
| Sarcura–SEVERAL: investment, 202211 seed plus financing round €7m co-led by Lansdowne Investment Co Cyprus + IST Cube |
2022-11-17 |
| Novigenix–SEVERAL: investment, 202211 financing round Series B first closing €? of €20m from existing + new investors |
2022-11-16 |
| Roche–Jnana Therapeutics: small-molecule drug discovery, 202211– collab + license $50m upfront + >2b milestones RAPID platform for multiple targets |
2022-11-15 |
| Neurescence–Bruker: investment, 202211 acquisition 100% of Neurescence Inc by Bruker |
2022-11-14 |
| BC Platforms–Jolt Capital: investment, 202211 growth financing round totalling CHF20m incl new + lead investor Jolt Capital |
2022-11-08 |
| BC Platforms–SEVERAL: investment, 202211 growth financing round CHF20m led by new investor Jolt Capital |
2022-11-08 |
| Inscopix–Bruker: investment, 202211 acquisition €na of Inscopix by Bruker |
2022-11-08 |
| Ayoxxa–NONE: investment, 202211– filed for bankruptcy |
2022-11-04 |
| Centogene–BC Platforms: data integration and analysis s/w, 202211– collab Centogene launches Biodata Network on BCRQUEST.com of BC Platforms |
2022-11-03 |
| Ono Pharmaceutical–Memo Therapeutics: antibody drug discovery, 202211– collab r+d antibodies for immuno-oncology targets |
2022-11-01 |
| Tamer Group–CellPhenomics: Reverse Clinical Engineering, 202211– collab sale of RCE of ASC Oncology by Tamer Group in MENA region |
2022-11-01 |
| Binding Site–Thermo Fisher: investment, 202210– acquisition £2.25b in cash from shareholder group led by Nordic Capital ANNOUNCED |
2022-10-31 |
| Cyclarity Therapeutics–Forever Healthy: investment, 202210 existent investor Kizoo Technology Capital |
2022-10-26 |
| MoglingBio–Forever Healthy: investment, 202210 seed financing with sole investor Kizoo Technology Capital |
2022-10-26 |
| Alto Neuroscience–SEVERAL: investment, 202210 financing round Series B $35m led by Lightswitch Capital + Alkeon Capital |
2022-10-25 |
| Evotec–MHH: biospecimen, 202210– collab access to SjS + SLE patient biospecimen for analysis with PanOmics platform to expand E.MPD database |
2022-10-25 |
| European Spatial Biology Center–Resolve Biosciences: Molecular Cartography technology, 202210 supply to ESBC existent |
2022-10-24 |
| Helmholtz–Resolve Biosciences: Molecular Cartography technology, 202210 supply to DKFZ existent as one of first customers |
2022-10-24 |
| Resolve Biosciences–Alafi Capital: investment, 202210 financing round Series B totalling $71m incl existing + co-investor Alafi Capital |
2022-10-24 |
| Resolve Biosciences–EDBI: investment, 202210 financing round Series B totalling $71m incl co-investor EDBI |
2022-10-24 |
| Resolve Biosciences–North Rhine-Westphalia (govt): investment, 202210 financing round Series B totalling $71m incl co-investor NRW.BANK |
2022-10-24 |
| Resolve Biosciences–Patient Square Capital: investment, 202210 financing round Series B totalling $71m incl lead investor Patient Square Capital |
2022-10-24 |
| Resolve Biosciences–PS Capital Management: investment, 202210 financing round Series B totalling $71m incl existing + co-investor PS Capital |
2022-10-24 |
| Resolve Biosciences–SEVERAL: investment, 202210 financing round Series B $71m led by Patient Square Capital |
2022-10-24 |
| Stanford Univ–Resolve Biosciences: Molecular Cartography technology, 202210 supply to Stanford Medicine Dept of Genetics existent |
2022-10-24 |
| Univ Copenhagen–Resolve Biosciences: Molecular Cartography technology, 202210 supply to Novo Nordisk Foundation Center existent |
2022-10-24 |
| VIB–Resolve Biosciences: Molecular Cartography technology, 202210 supply to VIB existent as one of first customers |
2022-10-24 |
| HMNC–SEVERAL: investment, 202210 financing round 1st closing €14.3m from new + existing investors |
2022-10-20 |
| Nucleome Therapeutics–Merck (DE): investment, 202210 financing round Series A totalling £37.5m incl new + lead investor M Ventures |
2022-10-19 |
| Nucleome Therapeutics–SEVERAL: investment, 202210 financing round Series A £37.5m led by M Ventures |
2022-10-19 |
| Anokion–Pfizer: investment, 202210 equity investment $35m through Pfizer Breakthrough Growth Initiative |
2022-10-18 |
| PBD Biotech–Foresight Group: investment, 202210 follow-on financing round totalling £2.4m incl co-lead investor Foresite Group via MEI Fund |
2022-10-17 |
| PBD Biotech–Mercia: investment, 202210 follow-on financing round totalling £2.4m incl co-lead investor Mercia via MEI Fund |
2022-10-17 |
| PBD Biotech–OTHER: investment, 202210 follow-on financing round totalling £2.4m incl private investors as co-investors |
2022-10-17 |
| PBD Biotech–SEVERAL: investment, 202210 follow-on financing round £2.4m co-led by Mercia + Foresight Group |
2022-10-17 |
| PBD Biotech–Univ Nottingham: investment, 202210 follow-on financing round totalling £2.4m incl co-investor Univ of Nottingham |
2022-10-17 |
| Bavaria (govt)–Osaka (govt): life sciences, 202210– collab third renewal of partnership of BioM + Osaka Bio Headquarters originally signed in 2011 |
2022-10-12 |
| Apollo Health Ventures–Trophic Communications: public relations, 202210 service existent by Trophic |
2022-10-11 |
| Focal Biosciences–Apollo Health Ventures: investment, 202210 founding investor Apollo HV launches Focal Biosciences with Paul Scherrer Institute |
2022-10-11 |
| Andera Partners–SEVERAL: investment, 202210 final closing of BioDiscovery 6 fund at €456m |
2022-10-10 |
| Immatics–SEVERAL: investment, 202210 underwritten offering $110m with 10.9m ordinary shares at $10.09/share |
2022-10-10 |
| Cevec–Danaher: investment, 202210 acquisition of Cevec by Cytiva |
2022-10-06 |
| Irubis–EU (govt): investment, 202210 seed financing round totalling €2.8m incl co-investor EIC Fund |
2022-10-06 |
| Irubis–High-Tech Gründerfonds: investment, 202210 seed financing round totalling €2.8m incl co-lead investor HTGF |
2022-10-06 |
| Irubis–OTHER: investment, 202210 seed financing round totalling €2.8m incl business angels as co-investors |
2022-10-06 |
| Irubis–SEVERAL: investment, 202210 seed financing round €2.8m led by HTGF + Verve Ventures + Ventura BioMed Investors |
2022-10-06 |
| Irubis–TU Munich: investment, 202210 seed financing round totalling €2.8m incl co-investor Initiative for Industrial Innovators |
2022-10-06 |
| Irubis–Ventura Biomed Investors: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Ventura Biomed Investors |
2022-10-06 |
| Irubis–Verve Capital Partners: investment, 202210 seed financing round totalling €2.8m incl co-lead investor Verve Ventures |
2022-10-06 |
| Araris Biotech–4BIO Ventures: investment, 202210 financing round totalling $24m incl existing + co-lead investor 4BIO Capital |
2022-10-04 |
| Araris Biotech–Bellevue: investment, 202210 financing round totalling $24m incl existing + co-lead investor Pureos Bioventures |
2022-10-04 |
| Araris Biotech–btov Partners: investment, 202210 financing round totalling $24m incl existing + co-investor btov Partners |
2022-10-04 |
| Araris Biotech–Institute for Follicular Lymphoma Innovation: investment, 202210 financing round totalling $24m incl new + co-investor IFLI |
2022-10-04 |
| Araris Biotech–Redalpine: investment, 202210 financing round totalling $24m incl existing + co-investor Redalpine |
2022-10-04 |
| Araris Biotech–Schroders: investment, 202210 financing round totalling $24m incl existing + co-investor Schroders Capital |
2022-10-04 |
| Araris Biotech–SEVERAL: investment, 202210 financing round $24m co-led by 4BIO Capital + Pureos Bioventures |
2022-10-04 |
| Araris Biotech–VI Partners: investment, 202210 financing round totalling $24m incl existing + co-investor VI Partners |
2022-10-04 |
| Araris Biotech–Wille Finance: investment, 202210 financing round totalling $24m incl new + co-investor Wille AG |
2022-10-04 |
| Sibylla Biotech–Helsinn: investment, 202210 financing round Series A totalling €23m incl co-investor 3B Future Health Fund II S.C.A. SICAV-RAIF |
2022-10-04 |
| Sibylla Biotech–SEVERAL: investment, 202210 financing round Series A €23m led by V-Bio Ventures |
2022-10-04 |
| Sibylla Biotech–Trophic Communications: public relations, 202210 service existent by Trophic |
2022-10-04 |
| Sibylla Biotech–VI Partners: investment, 202210 financing round Series A totalling €23m incl co-investor VI Partners |
2022-10-04 |
| Xund Solutions–Lana Ventures: investment, 202209 seed financing round totalling €6m incl co-investor Lana Ventures |
2022-09-29 |
| Xund Solutions–MassMutual: investment, 202209 seed financing round totalling €6m incl co-lead investor MassMutual Ventures |
2022-09-29 |
| Xund Solutions–MMC Ventures: investment, 202209 seed financing round totalling €6m incl co-lead investor MMC Ventures |
2022-09-29 |
| Xund Solutions–Roche: investment, 202209 seed financing round totalling €6m incl co-investor RoX Health |
2022-09-29 |
| Xund Solutions–SEVERAL: investment, 202209 seed financing round €6m co-led by MMC Ventures + MassMutual Ventures |
2022-09-29 |
| GS Bavaria–High-Tech Gründerfonds: investment, 202209 seed financing round totalling €7-figure incl lead investor HTGF |
2022-09-28 |
| GS Bavaria–OTHER: investment, 202209 seed financing round totalling €7-figure incl renowbed business angels |
2022-09-28 |
| GS Bavaria–SEVERAL: investment, 202209 seed financing round €7-figure led by HTGF |
2022-09-28 |
| Valneva–SEVERAL: investment, 202209–202210 private placement €100-45m of 20.5m ordinary shares at €4.9/share |
2022-09-28 |
| Valneva–SEVERAL: investment, 202209–202210 public offering $3.57m of 375k ADSs (each = 2 ordinary shares) at $9.51/ADS |
2022-09-28 |
| BioDGraft–NLC Ventures: investment, 202209 existent seed investor NLC |
2022-09-27 |
| Kupando–Brandenburg (govt): investment, 202209 financing round Series A totalling €13m incl co-investor Brandenburg Kapital |
2022-09-26 |
| Kupando–High-Tech Gründerfonds: investment, 202209 financing round Series A totalling €13m incl co-investor HTGF |
2022-09-26 |
| Kupando–LifeCare Partners: investment, 202209 financing round Series A totalling €13m incl co-lead investor LifeCare Partners |
2022-09-26 |
| Kupando–OTHER: investment, 202209 financing round Series A totalling €13m incl undisclosed family offices as co-investors |
2022-09-26 |
| Kupando–Remiges Ventures: investment, 202209 financing round Series A totalling €13m incl lead investor Remiges Ventures |
2022-09-26 |
| Kupando–SEVERAL: investment, 202209 financing round Series A €13m led by Remiges Ventures + co-led by LifeCare Partners |
2022-09-26 |
| Kupando–Ventura Biomed Investors: investment, 202209 financing round Series A totalling €13m incl co-investor Venture Biomed Investors |
2022-09-26 |
| Evotec–Adapsyn Biotechnology: drug discovery, 202209– strategic collab €na providing Evotec with accesss to drug-like small molecules for screening |
2022-09-21 |
| Hedera Dx–Air Street Capital: investment, 202209 seed financing round totalling €14m incl co-investor Air Street Capital |
2022-09-21 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
